Drug Trial Radar · NCT02573350
A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
213
Actual
Start
Mar 26, 2009
Primary completion
Oct 27, 2011
Study completion Oct 27, 2011
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Oct 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2, multicenter, uncontrolled, open-label trial in participants with Multi-drug Resistant Tuberculosis (MDR-TB). Only participants who completed Trial 242-07-204 (NCT00685360) were eligible. The trial was performed globally at 14 sites qualified to treat MDR-TB. All 434 participants who completed Trial 242-07-204 were eligible for this trial if there was still potential clinical benefit to them and all inclusion criteria and no exclusion criteria were met.
Conditions
- Tuberculosis, Multidrug-Resistant
Interventions
DelamanidDrug
Delamanid was administered orally twice daily as 50-mg tablets under fed conditions in the morning and evening.
OBRDrug
Selection and administration of the treatment medications (i.e. OBRs) was based on World Health Organization (WHO's) Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines. Study investigators could change OBR for a participant based on his/her tolerability and drug susceptibility testing (DST) results.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinically Significant Abnormality in Vital SignsTime frame: From first dose of study drug up to Week 26
- Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) ValuesTime frame: From first dose of study drug up to Week 26
- Number of Participants With Clinical Significant Abnormality in Laboratory TestTime frame: From first dose of study drug up to Week 26
- Number of Participants With Abnormality in Audiometry at BaselineTime frame: Baseline
- Number of Participants With Abnormality in Visual AcuityTime frame: From first dose of study drug up to Week 26
- Number of Participants With Abnormality in Neurological and Psychiatric Assessment Reported as Treatment-emergent Adverse Event (TEAE)Time frame: From first dose through 28 days after last dose of study drug (up to approximately 30 weeks)
- Number of Participants With Clinical Significant Abnormality in Thyroid Function Test Reported as TEAETime frame: From first dose through 28 days after last dose of study drug (up to approximately 30 weeks)
- Number of Participants With Any Concomitant Medication UsageTime frame: From first dose of study drug up to Week 26
- Percentage of Participants With At Least One TEAEs and Serious Adverse Events (SAEs)Time frame: From first dose through 28 days after last dose of study drug (up to approximately 30 weeks)
- Number of Participants With Clinical Significant Abnormality in Coagulation (PT and aPTT) Reported as TEAETime frame: From first dose through 28 days after last dose of study drug (up to approximately 30 weeks)
- Number of Participants With Clinical Significant Abnormality in CortisolTime frame: From first dose of study drug up to Week 26
Locations
8 sites in 6 countries. Site status is shown where the registry gives one.
Beijing Chest Hospital
Beijing, China
North Estonian Medical Centre Foundation Center of Pulmonology
Tallinn, Estonia
Tartu University Lung Hospital
Tartu, Estonia
State Agency of Tuberculosis and Lung Disease
Riga, Latvia
Hospital Nacional Sergio E. Bernales
Lima, Peru
Tropical Disease Foundation
Makati City, Philippines
Younsei University Medical Center
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.